Diabetologia:在印度和英国,使用移动技术促进可持续的生活方式改变以预防2型糖尿病

2020-04-12 MedSci原创 MedSci原创

这项随机对照试验是在印度和英国对糖尿病前期患者进行的,目的是研究手机短信服务(SMS)是否可以用来激励和教育人们改变生活方式,以预防2型糖尿病。

这项随机对照试验是在印度和英国对糖尿病前期患者进行的,目的是研究手机短信服务(SMS)是否可以用来激励和教育人们改变生活方式,以预防2型糖尿病。

研究对象为糖尿病前期患者(n = 2062;控制:n = 1031;干预:n = 1031) HbA1c≥42和≤47 mmol/mol(≥6.0%和≤6.4%)。参与者来自印度的公利和私人部门(年龄在35-55岁之间的男性和女性),以及英国的国民健康服务(NHS)健康检查计划(年龄在40-74岁之间,没有预先存在的糖尿病、心血管疾病或肾脏疾病)。在印度,使用计算机生成的序列(1:1)进行研究小组分配,在英国,则是按照排列的区块进行分层随机。两国的调查人员在整个研究期间都保持盲法。所有的参与者都得到了关于基本健康生活方式的建议。干预组每周2-3次通过手机短信收到支持性短信。在基线、6个月、12个月和24个月时对参与者进行评估。主要结果是转化为2型糖尿病,次要结果包括人体测量学、生物化学、饮食和身体活动变化、血压和生活质量。

随访2年(n = 2062;控制:n = 1031;干预:n = 1031),在意向治疗人群中,使用离散时间比例风险模型计算的2型糖尿病发展的HR为0.89 (95% CI 0.74, 1.07;p = 0.22)。次要结果无显著性差异。

这项在两个不同种族和文化背景的国家进行的试验表明,通过短信改变生活方式,在2年内没有显著降低糖尿病的进展。

原始出处:

Arun Nanditha, Hazel Thomson,A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639425, encodeId=22351639425ab, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 14 03:38:53 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761377, encodeId=74881e61377c5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Oct 09 18:38:53 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043060, encodeId=527110430608b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 12 23:38:53 CST 2020, time=2020-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639425, encodeId=22351639425ab, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 14 03:38:53 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761377, encodeId=74881e61377c5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Oct 09 18:38:53 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043060, encodeId=527110430608b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 12 23:38:53 CST 2020, time=2020-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639425, encodeId=22351639425ab, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu May 14 03:38:53 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761377, encodeId=74881e61377c5, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Oct 09 18:38:53 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043060, encodeId=527110430608b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 12 23:38:53 CST 2020, time=2020-04-12, status=1, ipAttribution=)]
    2020-04-12 misszhang

    谢谢MedSci提供最新的资讯

    0